These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26259807)

  • 21. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.
    Diab S; Teo T; Kumarasiri M; Li P; Yu M; Lam F; Basnet SK; Sykes MJ; Albrecht H; Milne R; Wang S
    ChemMedChem; 2014 May; 9(5):962-72. PubMed ID: 24677692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and biological evaluation of the pirfenidone derivatives as antifibrotic agents.
    Ma Z; Pan Y; Huang W; Yang Y; Wang Z; Li Q; Zhao Y; Zhang X; Shen Z
    Bioorg Med Chem Lett; 2014 Jan; 24(1):220-3. PubMed ID: 24332090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Continued exploration of the triazolopyridine scaffold as a platform for p38 MAP kinase inhibition.
    Jerome KD; Rucker PV; Xing L; Shieh HS; Baldus JE; Selness SR; Letavic MA; Braganza JF; McClure KF
    Bioorg Med Chem Lett; 2010 Jan; 20(2):469-73. PubMed ID: 19969459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-based design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine-based p38 MAP kinase inhibitors.
    Kaieda A; Takahashi M; Takai T; Goto M; Miyazaki T; Hori Y; Unno S; Kawamoto T; Tanaka T; Itono S; Takagi T; Hamada T; Shirasaki M; Okada K; Snell G; Bragstad K; Sang BC; Uchikawa O; Miwatashi S
    Bioorg Med Chem; 2018 Feb; 26(3):647-660. PubMed ID: 29291937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification and characterization of bi-thiazole-2,2'-diamines as kinase inhibitory scaffolds.
    Ngoei KR; Ng DC; Gooley PR; Fairlie DP; Stoermer MJ; Bogoyevitch MA
    Biochim Biophys Acta; 2013 Jun; 1834(6):1077-88. PubMed ID: 23410953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New modifications to the area of pyrazole-naphthyl urea based p38 MAP kinase inhibitors that bind to the adenine/ATP site.
    Moss N; Breitfelder S; Betageri R; Cirillo PF; Fadra T; Hickey ER; Kirrane T; Kroe RR; Madwed J; Nelson RM; Pargellis CA; Qian KC; Regan J; Swinamer A; Torcellini C
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4242-7. PubMed ID: 17560108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Pyrazolobenzothiazine Core as a New Chemotype of p38 Alpha Mitogen-Activated Protein Kinase Inhibitors.
    Sabatini S; Manfroni G; Barreca ML; Bauer SM; Gargaro M; Cannalire R; Astolfi A; Brea J; Vacca C; Pirro M; Massari S; Tabarrini O; Loza MI; Fallarino F; Laufer SA; Cecchetti V
    Chem Biol Drug Des; 2015 Oct; 86(4):531-45. PubMed ID: 25589097
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery and optimization of a series of 2-aminothiazole-oxazoles as potent phosphoinositide 3-kinase γ inhibitors.
    Oka Y; Yabuuchi T; Fujii Y; Ohtake H; Wakahara S; Matsumoto K; Endo M; Tamura Y; Sekiguchi Y
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7534-8. PubMed ID: 23122859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Docking, synthesis and pharmacological activity of novel urea-derivatives designed as p38 MAPK inhibitors.
    de Oliveira Lopes R; Romeiro NC; de Lima CK; Louback da Silva L; de Miranda AL; Nascimento PG; Cunha FQ; Barreiro EJ; Lima LM
    Eur J Med Chem; 2012 Aug; 54():264-71. PubMed ID: 22647219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Syntheses and structure-activity relationships for some triazolyl p38α MAPK inhibitors.
    Seerden JP; Leusink-Ionescu G; Leguijt R; Saccavini C; Gelens E; Dros B; Woudenberg-Vrenken T; Molema G; Kamps JA; Kellogg RM
    Bioorg Med Chem Lett; 2014 Mar; 24(5):1352-7. PubMed ID: 24508134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimization of alpha-ketoamide based p38 inhibitors through modifications to the region that binds to the allosteric site.
    Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Kucharski J; Lum C; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Urban J; Wang Z; Larson CJ
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4819-24. PubMed ID: 20663667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis and characterization of N', N"-diaryl ureas as p38 kinase inhibitors.
    Kulkarni RG; Laufer S; Mangannavar C; Garlapati A
    Med Chem; 2013 Mar; 9(2):213-21. PubMed ID: 22946566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis, p38α MAP kinase inhibition, anti-inflammatory activity, and molecular docking studies of 1,2,4-triazole-based benzothiazole-2-amines.
    Tariq S; Alam O; Amir M
    Arch Pharm (Weinheim); 2018 Apr; 351(3-4):e1700304. PubMed ID: 29611883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Azastilbenes: a cut-off to p38 MAPK inhibitors.
    Poon JF; Alao JP; Sunnerhagen P; Dinér P
    Org Biomol Chem; 2013 Jul; 11(27):4526-36. PubMed ID: 23719673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase.
    Kim DK; Lim JH; Lee JA; Dewang PM
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4006-10. PubMed ID: 18571921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of RO3201195 and a pyrazolyl ketone P38 MAPK inhibitor library on the proliferation of Werner syndrome cells.
    Bagley MC; Dwyer JE; Baashen M; Dix MC; Murziani PG; Rokicki MJ; Kipling D; Davis T
    Org Biomol Chem; 2016 Jan; 14(3):947-56. PubMed ID: 26611938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery and optimization of p38 inhibitors via computer-assisted drug design.
    Goldberg DR; Hao MH; Qian KC; Swinamer AD; Gao DA; Xiong Z; Sarko C; Berry A; Lord J; Magolda RL; Fadra T; Kroe RR; Kukulka A; Madwed JB; Martin L; Pargellis C; Skow D; Song JJ; Tan Z; Torcellini CA; Zimmitti CS; Yee NK; Moss N
    J Med Chem; 2007 Aug; 50(17):4016-26. PubMed ID: 17658737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacophore modeling of diverse classes of p38 MAP kinase inhibitors.
    Sarma R; Sinha S; Ravikumar M; Kishore Kumar M; Mahmood SK
    Eur J Med Chem; 2008 Dec; 43(12):2870-6. PubMed ID: 18406015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and synthesis of potent 1,2,4-trisubstituted imidazolinone derivatives with dual p38αMAPK and ERK1/2 inhibitory activity.
    Awadallah FM; Abou-Seri SM; Abdulla MM; Georgey HH
    Eur J Med Chem; 2015 Apr; 94():397-404. PubMed ID: 25778995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel lead structures for p38 MAP kinase via FieldScreen virtual screening.
    Cheeseright TJ; Holm M; Lehmann F; Luik S; Göttert M; Melville JL; Laufer S
    J Med Chem; 2009 Jul; 52(14):4200-9. PubMed ID: 19489590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.